CN Patent

CN1753661A — 用于治疗心脏及肾脏疾病的腺苷a1受体拮抗剂

Assigned to NovaCardia Inc · Expires 2006-03-29 · 20y expired

What this patent protects

本发明揭示一种医药组合物，其包含一β－阻断剂与一腺苷A1受体拮抗剂(AA1RA)、一血管紧张素转化酶(ACE)抑制剂与一腺苷A1受体拮抗剂(AA1RA)、及一血管紧张素II受体阻断剂(ARB)与一腺苷A1受体拮抗剂(AA1RA)。本发明也揭示治疗心血管疾病、肾脏疾病、碱中毒或糖尿病性肾病的方法，其包含确定一患者需要所述治疗，并给予所述患者本文揭示的医药组合物。

USPTO Abstract

本发明揭示一种医药组合物，其包含一β－阻断剂与一腺苷A1受体拮抗剂(AA1RA)、一血管紧张素转化酶(ACE)抑制剂与一腺苷A1受体拮抗剂(AA1RA)、及一血管紧张素II受体阻断剂(ARB)与一腺苷A1受体拮抗剂(AA1RA)。本发明也揭示治疗心血管疾病、肾脏疾病、碱中毒或糖尿病性肾病的方法，其包含确定一患者需要所述治疗，并给予所述患者本文揭示的医药组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN1753661A
Jurisdiction
CN
Classification
—
Expires
2006-03-29
Drug substance claim
No
Drug product claim
No
Assignee
NovaCardia Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.